CN110917053A - Anti-inflammatory composition - Google Patents
Anti-inflammatory composition Download PDFInfo
- Publication number
- CN110917053A CN110917053A CN201911241083.2A CN201911241083A CN110917053A CN 110917053 A CN110917053 A CN 110917053A CN 201911241083 A CN201911241083 A CN 201911241083A CN 110917053 A CN110917053 A CN 110917053A
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- inflammatory composition
- squalane
- inflammatory
- keratinocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Abstract
The invention discloses an anti-inflammatory composition, which comprises cannabidiol and squalane, wherein the mass ratio of the cannabidiol to the squalane is 1: 1-100. Through the mode, the anti-inflammatory composition disclosed by the invention can improve the inhibition effect of cannabidiol on IL-8 secretion in keratinocytes, so that the skin inflammatory reaction is reduced, the anti-inflammatory effect is realized, and the anti-inflammatory composition can be further used as a part in cosmetics, skin care, personal care and pharmaceutical formulations.
Description
Technical Field
The invention relates to the technical field of daily chemicals, in particular to an anti-inflammatory composition.
Background
The medicinal value of cannabis has long been known, but its use has been limited by its side effects such as addiction and psychogenic hallucination. Cannabidiol (CBD) is one of the main components of cannabinoids, is different from Tetrahydrocannabinol (THC), CBD has no side effects such as addiction and hallucinography, is a good antioxidant substance, and research shows that CBD has positive effects on human bodies, so that research and application of CBD are increasing year by year in recent years, and CBD legitimacy is announced in more than 50 countries around the world at present.
To date, more than 80 substances have been extracted from cannabis, one of which is CBD. CBD produces analgesia, and its pharmacology is mainly related to central cannabinoid receptor CB1 and peripheral cannabinoid receptor CB2, and the specific mechanism of action is still unknown at present. In addition, CBD has antiemetic, analgesic, antiinflammatory, antioxidant, antispasmodic, and anticancer effects. With the updating of regulations and the continuous study of application functions, low concentrations of CBD are emerging in health care, food and skin care products.
Keratinocytes (KC) are the most important cellular components of skin tissues and are also important components of the natural immune system of the skin, and IL-8 is an inflammatory cytokine secreted by keratinocytes and plays an important role in inflammatory skin disorders.
Disclosure of Invention
The invention mainly solves the technical problem of providing an anti-inflammatory composition which can relieve skin discomfort and relieve inflammation.
In order to solve the technical problems, the invention adopts a technical scheme that: an anti-inflammatory composition is provided, the anti-inflammatory composition comprises cannabidiol and squalane, and the mass ratio of the cannabidiol to the squalane is 1: 1-100.
In a preferred embodiment of the invention, the anti-inflammatory composition consists of cannabidiol and squalane, and the mass ratio of the cannabidiol to the squalane is 1: 1-100.
In a preferred embodiment of the invention, the source of cannabidiol is a plant extract source, a synthetic source or a fermentation source.
In a preferred embodiment of the invention, the cannabidiol is present in the form of a cannabis extract, a cannabis leaf extract, a cannabinoid or cannabidiol.
In a preferred embodiment of the present invention, the cannabidiol is one or more of cannabidiol, cannabidiol salt compounds or cannabidiol ester compounds.
In a preferred embodiment of the invention, the source of squalane is an animal extract source, a plant extract source or obtained by fermentation.
In a preferred embodiment of the invention, the source of squalane is obtained by fermentation.
In a preferred embodiment of the invention, the anti-inflammatory composition is used in cosmetic, skin care, personal care, pharmaceutical formulations.
In a preferred embodiment of the invention, the anti-inflammatory composition has an inhibitory effect on the secretion of IL-8 in keratinocytes.
In a preferred embodiment of the invention, the anti-inflammatory composition inhibits IL-8 secretion in keratinocytes more than cannabidiol inhibits IL-8 secretion in keratinocytes.
The invention has the beneficial effects that: the anti-inflammatory composition of the present invention can enhance the inhibitory effect of cannabidiol on IL-8 secretion in keratinocytes, thereby reducing the inflammatory response of the skin, achieving anti-inflammatory effects, and can be further used as part of cosmetic, skin care, personal care, pharmaceutical formulations.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
an anti-inflammatory composition is provided, the anti-inflammatory composition comprises cannabidiol and squalane, and the mass ratio of the cannabidiol to the squalane is 1: 1-100. In this example, the anti-inflammatory composition consisted of cannabidiol and squalane in a 1:5 mass ratio. It is within the scope of the present invention that the cannabidiol may be present in the form of a cannabis extract, a cannabis leaf extract, a cannabinoid, or cannabidiol. The anti-inflammatory composition has an inhibitory effect on the secretion of IL-8 in keratinocytes. The anti-inflammatory composition has a significantly higher inhibitory effect on IL-8 secretion in keratinocytes than cannabidiol.
HaCaT was treated with 10% fetal bovine serum, 100U/ml penicillin, 100. mu.g/ml streptomycin in RPMI 1640 at 37 ℃ with 5% CO2Culturing under saturated humidity condition. Selecting cells in logarithmic growth phase, inoculating the cells in a 96-well culture plate, culturing for 24h, completely attaching the cells to the wall, changing a culture medium into RPMI 1640 containing different test samples, incubating for 12h, collecting cell culture supernatant, and detecting the concentration of IL-8 in the supernatant by using a human IL-8ELISA kit. The results are as follows:
| IL-8 concentration (pg/ml) | Inhibition rate | |
| Blank space | 1367.59 | —— |
| 0.5μmol/L CBD | 1284.91 | 6% |
| 0.5. mu. mol/L CBD + 2.5. mu. mol/L squalane | 868.18 | 37% |
Example two:
the anti-inflammatory composition can be used in cosmetic, skin care, personal care, pharmaceutical formulations. The embodiment provides a high-efficiency anti-inflammatory emulsion, which consists of Alacel 165, a mixture of PEG-100 stearate and monoglyceride, shea butter, squalane, polydimethylsiloxane, VE acetate, CBD, xanthan gum, glycerol, butanediol, a preservative PE9010 and water, wherein the high-efficiency anti-inflammatory emulsion comprises the following components in percentage by weight: according to mass percentage, Alacel 1653.0%, shea butter 3.0%, squalane 3.0%, polydimethylsiloxane 3.0%, VE acetate 3.0%, CBD 3.0%, xanthan gum 3.0%, glycerin 3.0%, butanediol 3.0%, preservative PE 90103.0% and the balance of water.
The preparation method of the high-efficiency anti-inflammatory emulsion comprises the following steps: 1) heating PEG-100 stearate, monoglyceride, shea butter, squalane, polydimethylsiloxane, VE acetate and CBD to 80 deg.C for dissolving; 2) stirring xanthan gum, glycerol, butanediol and water, and heating to 80 deg.C; 3) adding the raw materials in the step (1) into the step (2), and homogenizing at high speed for 15 min; 4) adding PE9010, stirring and cooling to room temperature.
The squalane has a synergistic effect on cannabidiol, and other grease has no such effect. Meanwhile, the ratio of the cannabidiol to the squalane is not random, and the effect of the invention can be achieved only by specific combination with the mass ratio of 1: 1-100.
The invention has the beneficial effects that:
the anti-inflammatory composition can improve the inhibition effect of cannabidiol on IL-8 secretion in keratinocytes, thereby reducing skin inflammatory response and realizing anti-inflammation;
secondly, the anti-inflammatory composition can be further used as part of cosmetic, skin care, personal care, pharmaceutical formulations.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes, which are made by the present specification, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. An anti-inflammatory composition, characterized in that the anti-inflammatory composition comprises cannabidiol and squalane, wherein the weight ratio of cannabidiol to squalane is 1: 1-100.
2. The anti-inflammatory composition of claim 1, wherein the anti-inflammatory composition consists of cannabidiol and squalane in a weight ratio of cannabidiol to squalane of 1:1 to 100.
3. Anti-inflammatory composition according to claim 1, characterized in that the source of cannabidiol is of plant extract, synthetic or fermentation origin.
4. An anti-inflammatory composition as in claim 1, wherein cannabidiol is present in the form of a cannabis extract, a cannabis leaf extract, a cannabinoid, or cannabidiol.
5. An anti-inflammatory composition as claimed in claim 1, wherein the cannabidiol is one or more of cannabidiol, cannabidiol salts or cannabidiol esters.
6. Anti-inflammatory composition according to claim 1, characterized in that the source of squalane is of animal origin, of vegetable origin or obtained by fermentation.
7. Anti-inflammatory composition according to claim 6, characterized in that the source of squalane is obtained by fermentation.
8. Anti-inflammatory composition according to claim 1, characterized by the use of said anti-inflammatory composition in cosmetic, skin care, personal care, pharmaceutical formulations.
9. An anti-inflammatory composition according to claim 1, wherein said anti-inflammatory composition has an inhibitory effect on the secretion of IL-8 in keratinocytes.
10. An anti-inflammatory composition as claimed in claim 9, wherein the anti-inflammatory composition has a greater inhibitory effect on IL-8 secretion in keratinocytes than cannabidiol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911241083.2A CN110917053A (en) | 2019-12-06 | 2019-12-06 | Anti-inflammatory composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911241083.2A CN110917053A (en) | 2019-12-06 | 2019-12-06 | Anti-inflammatory composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917053A true CN110917053A (en) | 2020-03-27 |
Family
ID=69858130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911241083.2A Pending CN110917053A (en) | 2019-12-06 | 2019-12-06 | Anti-inflammatory composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110917053A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111793979A (en) * | 2020-07-28 | 2020-10-20 | 云南玉麻生物科技有限公司 | Preparation method of functional fabric based on hemp extract |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071149A (en) * | 2012-12-13 | 2013-05-01 | 浙江海力生生物科技有限公司 | Collagen and squalane composition, preparations thereof, and preparation methods and applications of composition and preparations |
| CN109414405A (en) * | 2016-03-31 | 2019-03-01 | 智能科技专题公司 | Delivery system |
| CN109394815A (en) * | 2018-12-28 | 2019-03-01 | 肖文秀 | A kind of infant's skin tonic composition and preparation method thereof |
| CN109498605A (en) * | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | A kind of composition for treating gynaecological imflammation and its application in topical composition |
| US20190247299A1 (en) * | 2018-02-15 | 2019-08-15 | C&A Innovations Corp. | Compositions and methods for treating eczema |
| CN110314106A (en) * | 2019-08-19 | 2019-10-11 | 云南绿新生物药业有限公司 | A kind of mildy wash and preparation method thereof of containing water-soluble cannabidiol |
| CN110327255A (en) * | 2019-08-12 | 2019-10-15 | 云南绿新生物药业有限公司 | A kind of mildy wash and preparation method thereof containing fiery numb essential oil |
-
2019
- 2019-12-06 CN CN201911241083.2A patent/CN110917053A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103071149A (en) * | 2012-12-13 | 2013-05-01 | 浙江海力生生物科技有限公司 | Collagen and squalane composition, preparations thereof, and preparation methods and applications of composition and preparations |
| CN109414405A (en) * | 2016-03-31 | 2019-03-01 | 智能科技专题公司 | Delivery system |
| CN109498605A (en) * | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | A kind of composition for treating gynaecological imflammation and its application in topical composition |
| US20190247299A1 (en) * | 2018-02-15 | 2019-08-15 | C&A Innovations Corp. | Compositions and methods for treating eczema |
| CN109394815A (en) * | 2018-12-28 | 2019-03-01 | 肖文秀 | A kind of infant's skin tonic composition and preparation method thereof |
| CN110327255A (en) * | 2019-08-12 | 2019-10-15 | 云南绿新生物药业有限公司 | A kind of mildy wash and preparation method thereof containing fiery numb essential oil |
| CN110314106A (en) * | 2019-08-19 | 2019-10-11 | 云南绿新生物药业有限公司 | A kind of mildy wash and preparation method thereof of containing water-soluble cannabidiol |
Non-Patent Citations (2)
| Title |
|---|
| 张宝元等: "天然中草药美白祛斑化妆品", 《日用化学品科学》 * |
| 陈丹萍等: "大麻二酚对HaCaT细胞分泌IL-8及IL-10的影响", 《中国麻风皮肤病杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111793979A (en) * | 2020-07-28 | 2020-10-20 | 云南玉麻生物科技有限公司 | Preparation method of functional fabric based on hemp extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101752451B1 (en) | Cosmetic composition having anti-inflammatory activity | |
| US20090036402A1 (en) | Use of compounds from centella asiatica | |
| JP2009184955A (en) | TYPE IV COLLAGEN PRODUCTION PROMOTER, TRANSGLUTAMINASE-1 PRODUCTION PROMOTER, SERINE PALMITOYLTRANSFERASE PRODUCTION PROMOTER, AQUAPORIN 3 PRODUCTION PROMOTER, INVOLUCRIN PRODUCTION PROMOTER, HMG-CoA REDUCTASE PRODUCTION PROMOTER AND ADENOSINE TRIPHOSPHATE PRODUCTION PROMOTER | |
| KR102144568B1 (en) | Composition for skin conditioning comprising Morus alba L. extract | |
| KR101892097B1 (en) | Cosmetic composition for reducing acne containing extract of senna tora | |
| CN108703909B (en) | Composition with anti-wrinkle and anti-aging effects and application of composition in cosmetics | |
| KR101528770B1 (en) | Cosmetic composition for alleviating sebum secretion and improving acne symptoms containing polyphenols derived from apple | |
| KR101204858B1 (en) | Cosmetic Composition for for improving Skin-Wrinkle | |
| CN110917053A (en) | Anti-inflammatory composition | |
| KR101029534B1 (en) | Composition for treating and improving skin disease comprising tree extract for propolis | |
| KR20160023310A (en) | Composition for anti-aging containing youngia denticulata extract | |
| KR101587447B1 (en) | Cosmetic composition with BL-S extract by the supercritical extraction with the effect of skin sebum control, skin barrier intention, skin moisture control and skin protection | |
| KR101578908B1 (en) | Extract of fermentative Zizyphus jujuba Fructus by Laetiporus sulphureus having lifespan extention of C. elegans via stress response and increasing collegen synthesis, and its cosmetic and therapeutic agent for wrinkle containing the same | |
| KR20190041691A (en) | Cosmetic composition for anti-allergy and for improving atopic dermatitis comprising extract of anemone reflexa stephan as active ingredient | |
| KR102272237B1 (en) | Composition for improved atopy skin and skin moisturizing comprising natural extract | |
| KR101555219B1 (en) | Cosmetic composition for inhibition of sebum secretion and acnes improvement comprising extracts mixture of Chrysanthemum zawadskii var. latilobum, Euphorbia lathyris and Pinus koraiensis | |
| JP6629271B2 (en) | Endo180 production promoter | |
| KR102622690B1 (en) | Cosmetic composition for protecting skin comprising mixed extracts of acer tegmentosum and magnolia sieboldii as active ingredient | |
| KR102504878B1 (en) | cosmetic composition having anti-inflammatory and skin soothing and effects and improvement of skin itching containing fermented extracts of Campsis grandiflora, Plum blossom, Quercus acuta THUNB | |
| KR102476671B1 (en) | Composition for skin conditioning comprising Scutellaria baicalensis Georgi extract | |
| KR102451839B1 (en) | Cosmetic composition comprising ginsenoside as active ingredient | |
| JP6262113B2 (en) | Collagen production promoter | |
| KR20160064704A (en) | Composition for antiinflammation and for improving skin acne containing icariside B6 | |
| CN116531274A (en) | Skin care composition derived from olive and application thereof | |
| KR101506863B1 (en) | Skin care compositions for antiwrinkle effect comprising the extracts of Areca catechu L. and Juncus effusus var. decipiens Buchen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |
|
| RJ01 | Rejection of invention patent application after publication |